Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREA S LUKES

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1669556718
CMS profile
211099
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$86,375.33

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $49,013.51 42
Myovant Sciences Inc. $34,748.93 30
PFIZER INC. $2,500.00 1
Novo Nordisk Inc $88.61 5
Lilly USA, LLC $24.28 1

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREA S LUKES

NPI 1669556718 · CMS profile ID 211099

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669556718?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREA S LUKES, NPI 1669556718, CMS profile ID 211099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669556718?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANDREA S LUKES, NPI 1669556718, CMS profile ID 211099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669556718?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANDREA S LUKES, NPI 1669556718, CMS profile ID 211099, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1669556718?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $86,375.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–79 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $101.5507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406835 CMS
AbbVie Inc. $1,350.0007/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406829 CMS
AbbVie Inc. $1,350.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406817 CMS
AbbVie Inc. $1,350.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406823 CMS
Myovant Sciences Inc. $15.2606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834966631 CMS
Novo Nordisk Inc $13.8006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811039729 CMS
Novo Nordisk Inc $17.2106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811039721 CMS
AbbVie Inc. $1,350.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406811 CMS
AbbVie Inc. $19.6805/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406799 CMS
AbbVie Inc. $1,350.0005/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406805 CMS
AbbVie Inc. $1,350.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406795 CMS
Novo Nordisk Inc $22.4405/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810843825 CMS
AbbVie Inc. $1,350.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406789 CMS
AbbVie Inc. $1,350.0005/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406783 CMS
AbbVie Inc. $1,350.0004/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406777 CMS
AbbVie Inc. $1,350.0004/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406771 CMS
AbbVie Inc. $1,350.0004/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406765 CMS
Myovant Sciences Inc. $3,400.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834966625 CMS
AbbVie Inc. $26.8304/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406759 CMS
AbbVie Inc. $1,350.0003/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406753 CMS
AbbVie Inc. $1,350.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406747 CMS
AbbVie Inc. $1,350.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406741 CMS
Novo Nordisk Inc $14.0803/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811039715 CMS
AbbVie Inc. $1,350.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406736 CMS
AbbVie Inc. $1,350.0002/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406729 CMS
AbbVie Inc. $1,350.0002/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406725 CMS
AbbVie Inc. $1,350.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406719 CMS
AbbVie Inc. $26.4701/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406713 CMS
AbbVie Inc. $29.3601/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795406707 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $90,639.16 101
PY2020 $35,653.57 40
PY2021 $86,375.33 79
PY2022 $44,222.16 48
PY2023 $22,468.59 47
PY2024 $2,750.65 44
PY2025 $7,623.21 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $139,375.98 66
PY2024 Principal investigator $224,649.29 79
PY2023 Principal investigator $359,322.99 74
PY2022 Principal investigator $244,534.74 77
PY2021 Principal investigator $346,721.58 83
PY2020 Principal investigator $148,505.88 106
PY2019 Principal investigator $388,109.36 149

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $137.80 12/17/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228750051
Principal investigator 1 Sumitomo Pharma America, Inc. $357.21 12/17/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176657395
Principal investigator 1 Sumitomo Pharma America, Inc. $325.12 12/11/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176657126
Principal investigator 1 ABBVIE INC. $1,891.10 12/04/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202528530
Principal investigator 1 Sumitomo Pharma America, Inc. $184.15 12/04/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176657015
Principal investigator 1 Sumitomo Pharma America, Inc. $1,300.00 12/04/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176657019
Principal investigator 1 Sumitomo Pharma America, Inc. $562.61 11/20/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655846
Principal investigator 1 Sumitomo Pharma America, Inc. $2,250.18 11/19/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176655801
Principal investigator 1 PFIZER INC. $2,424.42 11/07/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228737154
Principal investigator 1 ABBVIE INC. $270.70 11/04/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202520133
Principal investigator 1 PFIZER INC. $2,700.02 11/04/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738778
Principal investigator 1 Sumitomo Pharma America, Inc. $1,085.85 10/30/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176651730
Principal investigator 1 Organon Llc $2,500.00 10/24/2025 Non-covered Recipient Entity
Carolina Women's Research and Wellness Ctr
8415-060 No dispute reported 06/30/2026 1173042352
Principal investigator 1 Sumitomo Pharma America, Inc. $562.61 10/09/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176650611
Principal investigator 1 Sumitomo Pharma America, Inc. $707.39 10/09/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176650617
Principal investigator 1 Sumitomo Pharma America, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176650316
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 10/01/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176650320
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 10/01/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176650324
Principal investigator 1 ABBVIE INC. $950.00 09/15/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202510918
Principal investigator 1 Sumitomo Pharma America, Inc. $1,085.85 09/11/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176647471
Principal investigator 1 Sumitomo Pharma America, Inc. $707.39 09/04/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176647116
Principal investigator 1 ABBVIE INC. $953.20 09/03/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202507433
Principal investigator 1 PFIZER INC. $5,122.00 08/29/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228785787
Principal investigator 1 Sumitomo Pharma America, Inc. $357.21 08/27/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176644648
Principal investigator 1 ABBVIE INC. $4,616.30 08/21/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202505403
Principal investigator 1 ABBVIE INC. $457.90 08/21/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202505405
Principal investigator 1 Sumitomo Pharma America, Inc. $16,663.59 08/13/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176643989
Principal investigator 1 ABBVIE INC. $541.40 08/05/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202501486
Principal investigator 1 PFIZER INC. $137.80 08/05/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228761178
Principal investigator 1 Sumitomo Pharma America, Inc. $693.90 07/18/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176640851
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 07/18/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176640855
Principal investigator 1 Sumitomo Pharma America, Inc. $357.21 07/11/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176640590
Principal investigator 1 PFIZER INC. $10,083.00 07/02/2025 Non-covered Recipient Entity
Carolina Womens Research and Wellness Center
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228788045
Principal investigator 1 Mylan Inc. $254.80 06/30/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH AND WELLNESS CENTER
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883475
Principal investigator 1 Sumitomo Pharma America, Inc. $1,631.75 06/18/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176636448
Principal investigator 1 ABBVIE INC. $963.60 06/03/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202488879
Principal investigator 1 Sumitomo Pharma America, Inc. $3,263.49 06/02/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176635569
Principal investigator 1 Sumitomo Pharma America, Inc. $83.70 06/02/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176635787
Principal investigator 1 Sumitomo Pharma America, Inc. $260.55 06/02/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176635798
Principal investigator 1 Sumitomo Pharma America, Inc. $7,495.33 05/14/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176634721
Principal investigator 1 ABBVIE INC. $3,603.60 05/07/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202483841
Principal investigator 1 ABBVIE INC. $270.70 05/06/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202482123
Principal investigator 1 Sumitomo Pharma America, Inc. $1,306.78 04/24/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633615
Principal investigator 1 Mylan Inc. $2,000.00 04/23/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH AND WELLNESS CENTER
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883473
Principal investigator 1 Sumitomo Pharma America, Inc. $4,824.60 04/10/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633175
Principal investigator 1 Organon Llc $1,200.00 04/04/2025 Non-covered Recipient Entity
Carolina Women's Research and Wellness Ctr
8415-060 No dispute reported 06/30/2026 1173042626
Principal investigator 1 ABBVIE INC. $270.70 04/03/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202472930
Principal investigator 1 ABBVIE INC. $1,348.90 03/06/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202457785
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 03/05/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176630151
Principal investigator 1 Sumitomo Pharma America, Inc. $83.70 03/05/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176630170
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 03/05/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176630174
Principal investigator 1 Sumitomo Pharma America, Inc. $300.00 03/05/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176630178
Principal investigator 1 Sumitomo Pharma America, Inc. $5,177.12 02/21/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628371
Principal investigator 1 Sumitomo Pharma America, Inc. $562.61 02/20/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176628340
Principal investigator 1 Sumitomo Pharma America, Inc. $1,300.00 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176625798
Principal investigator 1 Sumitomo Pharma America, Inc. $2,100.83 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176626012
Principal investigator 1 Sumitomo Pharma America, Inc. $562.61 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627168
Principal investigator 1 Sumitomo Pharma America, Inc. $2,240.00 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627172
Principal investigator 1 Sumitomo Pharma America, Inc. $562.61 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627200
Principal investigator 1 Sumitomo Pharma America, Inc. $3,000.00 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627205
Principal investigator 1 Sumitomo Pharma America, Inc. $952.50 02/06/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627208
Principal investigator 1 ABBVIE INC. $541.40 02/05/2025 Non-covered Recipient Entity
CAROLINA WOMENS RESEARCH AND WELLNESS CENTER
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202444319
Principal investigator 1 Sumitomo Pharma America, Inc. $10,741.89 01/16/2025 Non-covered Recipient Entity
CAROLINA WOMEN'S RESEARCH & WELLNESS CTR
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624179
Principal investigator 1 Sumitomo Pharma America, Inc. $675.00 01/10/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624114
Principal investigator 1 Sumitomo Pharma America, Inc. $1,196.10 01/10/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624117
Principal investigator 1 Sumitomo Pharma America, Inc. $16,265.20 01/03/2025 Non-covered Recipient Entity
CWRWC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176623754

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $1.00 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $1.00 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $1.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $1.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $1.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2020–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to repurchase by UPM Holdings and physicians do not receive distributions of any kind related to the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1063739396
PY2023 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to repurchase by UPM Holdings and physicians do not receive distributions of any kind related to the GPO. Physician Covered Recipient No dispute reported 06/30/2026 973335833
PY2022 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare LP the operator of the GPO share a common general partner Unified Physician Management GP LLC. The Interest is not freely transferable remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 862655725
PY2021 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings's and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 798276141
PY2020 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings's and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 731157379